Erythropoietin

Erslev, Allan J.

doi:10.1056/nejm199105093241907

Cited by 334 publications

(101 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We have also compared the APP response to changes in plasma levels of the glycoprotein hormone erythropoietin (EPO), which is normally produced in inverse relationship to oxygen supply [10,11]. In addition, human volunteers were exposed to hypobaric hypoxia in a low pressure chamber in order to test for a direct effect of more prolonged, moderate hypoxia on APP production.…”

Section: Introductionmentioning

confidence: 99%

Kinetics and characteristics of an acute phase response following cardiac arrest

Oppert¹,

Gleiter

Müller

et al. 1999

Intensive Care Med

View full text Add to dashboard Cite

(i) A marked acute phase response occurs regularly after cardiac arrest, but within the complexity of this situation the severity of hypoxia is not a predominant determinant of this response. (ii) Despite in vitro evidence for similarities in the oxygen dependent regulation of APP and EPO production, the oxygen sensitivity of these proteins in vivo is different. (iii) Measurements of APP are not revealing regarding infectious complications in the early phase after CPR.

show abstract

Section: Introductionmentioning

confidence: 99%

Kinetics and characteristics of an acute phase response following cardiac arrest

Oppert¹,

Gleiter

Müller

et al. 1999

Intensive Care Med

View full text Add to dashboard Cite

show abstract

“…Although the most widely recognized cause of erythropoietin-deficient anemia is advanced chronic renal failure [10], the renal function in our patient was normal throughout the clinical course. No causes of the anemia such as infection, hemolysis, bleeding, cancer, collagen disease, or iron, vitamin B 12 , or folic acid deficiencies were detected by extensive laboratory examinations.…”

Section: Discussionmentioning

confidence: 99%

Simultaneous Improvement of Minimal-Change Nephrotic Syndrome and Anemia with Steroid Therapy

Yabana

Kihara

Toya

et al. 1999

Nephron

View full text Add to dashboard Cite

A 56-year-old man presented with transient anemia in minimal-change nephrotic syndrome. Following nephrotic syndrome, anemia suddenly appeared without renal dysfunction. The anemia might be attributable to hemodilution because of significant correlations between the values of hemoglobin concentration and serum total protein or blood urea nitrogen during the clinical course. A low serum level and a low urinary excretion of erythropoietin were found, and when nephrotic syndrome ameliorated with steroid therapy, urinary erythropoietin excretion and anemia disappeared. This case indicated disappearance of the exponential increase of endogenous erythropoietin in acute anemia in nephrotic syndrome probably due to urinary losses and altered biosynthesis of erythropoietin. We report a case of the simultaneous improvement of both nephrotic syndrome and anemia with steroid therapy.

show abstract

“…Conversely, Wenzel et al [14] observed that EPO levels before coronary artery surgery were within normal ranges. Firstly, we thought about a negative feedback, which has been well described [5] and is a common phenomenon in human physiology. When satisfactory haemoglobin concentration is achieved, there is no need for extensive EPO secretion, and in this case a lower EPO level could be a mechanism preventing polycythaemia.…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, it is also suggested that EPO could be given a few days before operation, to increase red cell mass in elective patients who are at risk for postoperative anaemia and depressed endogenous EPO production (recommendation class IIB, level of evidence C) [3]. In fact, the latter recommendation pertains to patients with impaired renal function, who often suffer from EPO deficiency [4,5]. Nephrologists commonly use rH-EPO in anaemic patients with advanced kidney disease.…”

Section: Introductionmentioning

confidence: 99%

Endogenic erythropoietin secretion in patients undergoing off-pump coronary artery bypass grafting

Drohomirecka

Kuśmierczyk²,

Kocańda³

et al. 2017

Kardiol Pol

View full text Add to dashboard Cite

A b s t r a c tBackground: Erythropoietin (EPO) deficiency or inadequate EPO secretion in response to bleeding may result in profound or prolonged anaemia after cardiac surgery. Aim:The aim of the study was to evaluate the changes in EPO secretion in patients undergoing off-pump coronary artery bypass grafting (OPCAB).Methods: Blood samples from 43 patients (mean age 65.1 ± 7.6 years) were obtained before surgery and on the 1 st , 2 nd , and 6 th day post isolated OPCAB. EPO levels ≥ 4.3 mIU/mL were considered normal.Results: Thirteen (30%) patients had the preoperative EPO level below normal range even though their preoperative haemoglobin was ≥ 13 g/dL. In patients with basal EPO deficiency lower peak EPO levels were observed compared to the group with normal basal EPO levels, even though reduction in haemoglobin concentrations was comparable in both groups. Moreover, lower reticulocytosis was noted on day 1 (8.5 ± 4.0‰ vs. 11.7 ± 4.4‰; p = 0.04) and a tendency toward lower values was seen on day 2 (9.6 ± 4.3‰ vs. 13.0 ± 5.8‰; p = 0.07) among patients with preoperative EPO deficiency.Conclusions: Erythropoietin deficiency is common in patients scheduled for OPCAB, and it results in diminished increase in EPO secretion in response to bleeding. Consequently, in patients with EPO deficiency, reticulocytosis is lower than it could be predicted based on the observation of patients with normal EPO levels and similar blood loss.

show abstract

Erythropoietin

Cited by 334 publications

References 45 publications

Kinetics and characteristics of an acute phase response following cardiac arrest

Kinetics and characteristics of an acute phase response following cardiac arrest

Simultaneous Improvement of Minimal-Change Nephrotic Syndrome and Anemia with Steroid Therapy

Endogenic erythropoietin secretion in patients undergoing off-pump coronary artery bypass grafting

Contact Info

Product

Resources

About